New treatment approach tested for rare blood disorder in malawi
NCT ID NCT04585893
Summary
This study is testing whether a drug called rituximab is safe and effective for treating multicentric Castleman disease in Malawi. The trial involves 15 adults with active disease who receive four weekly doses of rituximab, with higher-risk patients also receiving chemotherapy. Researchers will monitor patients for two years to track side effects, survival, and whether symptoms improve.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTICENTRIC CASTLEMAN DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UNC Project, Kamuzu Central Hospital
Lilongwe, Malawi
Conditions
Explore the condition pages connected to this study.